PCN120 COST-UTILITY OF DOCETAXEL COMPARED WITH BEST SUPPORTIVE CARE AND PEMETREXED IN SECOND LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN POLAND
Abstract
Authors
J Rutkowski B Gwiosda B Lisiecka M Wladysiuk J Lis R Plisko P Rys